Loading
Journal of Diabetes and Clinical Research
ISSN: 2689-2839
Ephrin B1 Regulates Inflammatory Pathways in Retinal Müller Cells
The role of inflammation has been accepted as a factor in the complications of diabetic retinopathy. Discovery of the upstream regulation of these inflammatory factors has remained a challenge. In this study, we explored the actions of ephrin B1 in retinal Müller cells and their actions on inflammatory proteins. We used diabetic human and mouse samples, as well as Müller cells in culture to measure ephrin B1 in Müller cells.
J Diabetes Clin Res, 2024, Volume 6, Issue 1, p1-7 | DOI: 10.33696/diabetes.6.056A Clinical Case Report: Utility of Amniotic Membrane in Treating a Geriatric Diabetic Patient with a Chronic Pressure Ulcer
Chronic wound closure is the inability for a wound to progress through the standard wound healing stages and timeframe, often stalling during the inflammatory stage. This paper presents a two-year open wound endured by a Native American patient of geriatric age and uncontrolled type II diabetes based on elevated A1c levels. Multiple therapeutic modalities had been attempted to close the wound, without improvement.
J Diabetes Clin Res, 2024, Volume 6, Issue 1, p8-14 | DOI: 10.33696/diabetes.6.057Use of Sodium-Glucose Co-transporter-2 Inhibitors after Acute Myocardial Infarction
Whether sodium-glucose co-transporters-2 (SGLT2) inhibitors have beneficial effects on cardiovascular (CV) events and mortality if given within few days from acute myocardial infarction (AMI) is unknown. The DAPA-MI trial (n= 4,107) is the only available study designed to evaluate the impact of administration of dapagliflozin on CV outcomes and mortality if started within 10 days from occurrence of an AMI.
J Diabetes Clin Res, 2024, Volume 6, Issue 1, p15-17 | DOI: 10.33696/diabetes.6.058Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes
The glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide is effective for the treatment of obesity and type 2 diabetes mellitus (T2DM). The purpose of this article is to define the therapeutic role of semaglutide for obesity-related heart failure with preserved ejection fraction (HF-pEF). Methods: Critical review of 2 recent randomized trials, the Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) and STEP-HFpEF DM.
J Diabetes Clin Res, 2024, Volume 6, Issue 1, p18-23 | DOI: 10.33696/diabetes.6.059Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.